The use of pembrolizumab as first-line therapy is indicated for patients with advanced NSCLC tumors positive for PD-L1 and EGFR/ALK wild-type, emphasizing the need for molecular testing before therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.